IKT
Inhibikase Therapeutics Inc
NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY
$1.86
-1.76% today
Updated 2026-06-03
Market cap
$268.03M
P/E ratio
—
P/S ratio
10.39x
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $2
Volume
0.8M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D7.3
Quality
B+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
11.6
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$5.88
+216.13%
12-Month target
$1.63
-12.37%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 11.56 — safe zone
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-12.06M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $123440.00 | $260500.00 | $0.00 | $0.00 | $1.00 |
| Net income | $-18.05M | $-19.03M | $-27.52M | $-48.26M | $-16.38M |
| EPS | — | — | — | — | $-0.44 |
| Free cash flow | $-17.59M | $-18.10M | $-19.15M | $-27.80M | $-12.06M |
| Profit margin | -14,625.85% | -7,304.75% | — | — | — |
Peer comparison
Smart narrative
Inhibikase Therapeutics Inc trades at $1.86. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 11.56, it sits in the safe zone. TTM revenue stands at $1.00.
Frequently asked questions
What is Inhibikase Therapeutics Inc's stock price?
Inhibikase Therapeutics Inc (IKT) trades at $1.86, on a P/S of 10.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Inhibikase Therapeutics Inc overvalued?
Inhibikase Therapeutics Inc carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Inhibikase Therapeutics Inc (IKT)?
The 12-month analyst consensus target is $5.88, about 216.1% above the current $1.86. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Inhibikase Therapeutics Inc's revenue?
Inhibikase Therapeutics Inc's trailing twelve-month revenue is $1.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Inhibikase Therapeutics Inc's Altman Z-Score is 11.56, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.39x
ROE-69.91%
Beta0.97
50D MA$1.80
200D MA$1.71
Shares out0.13B
Float0.09B
Short ratio—
Avg volume0.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—